GLP-1 Weight Loss Medications in 2025: What Semaglutide Really Does

The GLP-1 Revolution in Medical Weight Loss

If you have been following health news over the past few years, you have almost certainly heard about semaglutide — sold under the brand names Ozempic (for diabetes) and Wegovy (for weight loss) — and its newer, more potent companion tirzepatide (Mounjaro for diabetes, Zepbound for weight loss). These medications belong to a class called GLP-1 receptor agonists, and they have fundamentally changed what is possible in medical weight management.

For decades, medical weight loss was defined by modest results. Diet and exercise alone typically produced 3–5% weight loss that was difficult to sustain. The older weight loss medications approved before GLP-1 agents rarely exceeded 8–10% body weight reduction. GLP-1 medications have changed the conversation entirely — delivering results that approach the outcomes of bariatric surgery, with a much lower risk profile.

At Viva Medical Center in Doral, FL, our weight loss doctor team uses GLP-1 therapies as part of a comprehensive, medically supervised weight management program. Here is what the science says.

How GLP-1 Receptor Agonists Work

GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in your gut after eating. It signals your pancreas to release insulin, tells your liver to reduce glucose output, slows gastric emptying (making you feel full longer), and — critically — acts on appetite centers in the brain to reduce hunger and food cravings. GLP-1 receptor agonists are synthetic versions of this hormone, designed to be more potent and longer-lasting than the natural molecule.

Tirzepatide (Mounjaro/Zepbound) goes a step further, acting as a dual GIP and GLP-1 receptor agonist — targeting two appetite-regulating hormones simultaneously, which accounts for its superior efficacy compared to semaglutide alone.

What the 2024–2025 Clinical Data Shows

The clinical evidence for GLP-1 medications is now extensive and compelling. Here are the key findings from recent trials and real-world studies:

• SURMOUNT-5 Trial (2024): In a head-to-head comparison of tirzepatide versus injectable semaglutide in adults with obesity but without diabetes, tirzepatide achieved significantly greater weight loss — an average of 20.2% body weight reduction versus 13.7% for semaglutide at 72 weeks. Tirzepatide patients were 3.24 times more likely to achieve 15% or greater weight loss.
• Real-world persistence data (2025): Among patients persistent with GLP-1 therapy for 12 months or more, median weight loss reached 14.4% (interquartile range 9.5%–20.5%), confirming that clinical trial results translate meaningfully to real-world practice.
• SELECT Trial (semaglutide, cardiovascular outcomes): In patients with obesity and established cardiovascular disease but without diabetes, semaglutide reduced major cardiovascular events (MACE) by 20% (hazard ratio 0.80) and all-cause mortality by 19% (hazard ratio 0.81). This was a landmark finding — demonstrating that GLP-1 therapy benefits extend well beyond weight loss.
• Comparative advantage: Patients receiving tirzepatide were 1.76 times more likely to achieve 5% or greater weight loss and 2.54 times more likely to achieve 10% or greater weight loss compared to those on semaglutide, in clinical comparison data.

Who Is a Candidate for GLP-1 Weight Loss Therapy?

Current FDA approvals and clinical guidelines support GLP-1 receptor agonist use for weight loss in adults who meet the following criteria:

• BMI of 30 or greater (obesity), OR
• BMI of 27 or greater (overweight) with at least one weight-related comorbidity — such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea

For patients with type 2 diabetes, GLP-1 medications serve the dual purpose of improving blood sugar control AND promoting weight loss — making them uniquely valuable in the management of both conditions simultaneously.

What to Expect: Starting GLP-1 Therapy

GLP-1 medications are started at a low dose and gradually increased (titrated) over several weeks to months, with the goal of reaching the highest dose you can tolerate that achieves your weight loss target. This gradual titration is essential for minimizing side effects.

Common side effects are primarily gastrointestinal and include nausea, vomiting, diarrhea, and constipation — particularly during dose escalation. These typically improve as your body adjusts. Eating smaller, more frequent meals, staying well hydrated, and avoiding high-fat or spicy foods during the titration phase significantly reduces GI discomfort.

Weight loss trajectory: Most patients see meaningful weight loss within the first 4–8 weeks. Maximum weight loss typically occurs at 12–18 months of treatment. Unlike fad diets, GLP-1 therapy produces fat mass loss while preserving lean muscle mass, particularly when combined with adequate protein intake and resistance training.

Insurance and cost: Coverage for GLP-1 medications varies significantly by insurance plan. Wegovy and Zepbound are increasingly covered for obesity treatment, and both are typically covered for patients with type 2 diabetes under most plans. Our team at Viva Medical Center can help you navigate prior authorization, manufacturer savings programs, and alternatives if your insurance does not cover these medications.

GLP-1 Therapy Is a Tool, Not a Magic Pill

The most important thing to understand about GLP-1 medications is this: they are extraordinarily effective tools, but they work best as part of a comprehensive program that includes dietary changes, physical activity, behavioral support, and ongoing medical supervision. Weight regain after discontinuation is common — typically 50–66% of lost weight returns within one to two years of stopping — which is why we discuss long-term management strategy with every patient before starting treatment.

At Viva Medical Center, our weight loss doctor team does not simply write a prescription and send you home. We provide structured follow-up, nutritional guidance, progress monitoring, and adjustment of your plan as your needs evolve.

Start Your Medical Weight Loss Journey in Miami

If you are considering semaglutide in Miami or exploring GLP-1 therapy options, Viva Medical Center in Doral, FL is your partner. Our board-certified physicians provide medically supervised weight loss programs tailored to your goals, health history, and budget. We serve patients from Doral, Hialeah, Kendall, Sweetwater, and all of Miami-Dade. Call today or book your consultation online. Hablamos español.